期刊
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
卷 23, 期 2, 页码 369-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.soc.2013.11.004
关键词
Bile duct cancer cholangiocarcinoma; Hepatocellular carcinoma; Systemic therapy; Chemotherapy; Targeted therapies
Tumors of the biliary tract and hepatocellular carcinoma (HOC) are complex tumors with heterogeneous carcinogenic mechanisms. Patients with hepatobiliary cancer have advanced disease and need systemic therapy to palliate symptoms and extend survival. Development of effective systemic therapy is a significant unmet medical need. It is hoped that current and future clinical trials will identify additional effective systemic agents, combination systemic therapies, and combined modality options. The HCC community needs validated biomarkers to help identify the patients who will benefit most from emerging treatment options.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据